sorrento
releases
positive
results
phase
trial
resiniferatoxin
rtx
reduction
osteoarthritis
oa
knee
pain
phase
safety
data
month
day
efficacy
data
available
patients
enrolled
dose
limiting
toxicities
doses
tested
ug
months
study
scheduled
complete
last
patient
year
dose
selected
likely
optimal
therapeutic
dose
future
clinical
trials
durable
signal
weeks
justifies
initiation
phase
dose
confirmation
active
drug
saline
control
pain
control
patients
advanced
disease
grade
show
persistence
relief
beyond
months
composite
womac
suggests
rtx
could
promising
alternative
control
refractory
pain
patients
candidates
elective
joint
replacement
san
diego
globe
newswire
sorrento
therapeutics
nasdaq
srne
sorrento
released
positive
phase
trial
data
resiniferatoxin
rtx
completed
day
effectiveness
data
analysis
patients
completed
doses
patients
enrolled
negative
safety
signal
september
david
leiman
md
board
certified
anesthesiologist
clinical
assistant
professor
surgery
university
texas
houston
director
chronic
pain
lotus
clinical
research
houston
texas
lead
investigator
clinical
trial
commented
rtx
promising
new
treatment
fits
clear
unmet
need
osteoarthritis
patients
particularly
traditional
pain
management
options
insufficient
come
significant
drawbacks
encountered
opioids
participating
trial
interacting
treated
patients
looking
forward
day
rtx
might
approved
would
another
much
needed
tool
specialty
help
address
difficult
control
phase
trial
placebo
controlled
ascending
dose
study
extension
assess
safety
preliminary
efficacy
administration
rtx
saline
control
placebo
group
treatment
moderate
severe
pain
due
osteoarthritis
oa
knee
expanded
dose
confirmation
cohort
validate
safety
efficacy
selected
therapeutic
dose
compared
individual
baseline
abstract
presenting
intermediate
data
accepted
osteoarthritis
research
society
international
oarsi
meeting
held
may
meeting
cancelled
due
restrictions
abstract
released
embargo
accessed
conference
website
oarsi
conference
posters
page
strong
results
prompted
company
rapidly
advance
investigational
drug
product
phase
clinical
trial
active
drug
saline
control
expected
start
subsequent
phase
clinical
trial
expected
start
completing
additional
enabling
preclinical
studies
updated
safety
outcome
primary
ten
subjects
received
single
injection
subjects
received
single
rtx
injection
majority
subjects
dosed
resiniferatoxin
Âµg
dose
limiting
toxicities
observed
subjects
dosed
rtx
dose
level
studied
adverse
events
teaes
expected
based
mechanism
action
drug
included
pain
tachycardia
hypertension
resolved
less
day
mild
moderate
pain
reported
expected
nearly
subjects
dosed
rtx
well
subjects
treated
saline
control
managed
analgesics
pain
drug
administration
typically
subsided
within
hours
special
requirements
knee
cooling
local
anesthetics
application
used
study
table
subjects
adverse
events
study
teae
category
subjects
dosed
rtx
subjects
dosed
saline
control
teae
moderate
teae
severe
teae
fatal
teae
serious
teae
teae
considered
related
study
treatment
severe
teae
considered
related
study
treatment
serious
teae
considered
related
study
treatment
updated
e
fficacy
outcomes
secondary
magnitude
difference
treatment
effect
versus
saline
control
placebo
used
ascending
dose
portion
study
weeks
exceeded
traditionally
considered
sufficient
support
regulatory
approval
based
greater
points
reduction
womac
scale
question
pain
walking
flat
surface
compared
placebo
rtx
dose
selected
upcoming
clinical
trials
ug
womac
score
day
showed
average
reduction
relative
baseline
rtx
average
reduction
relative
saline
control
placebo
fast
relief
less
week
durability
effect
days
confirm
clinical
potential
drug
control
pain
associated
oa
knee
study
designed
follow
patients
day
patients
also
given
option
followed
longer
period
time
rtx
treated
patients
good
initial
response
evaluated
day
showed
pain
relief
levels
equivalent
response
likely
persistence
effect
exploratory
advanced
disease
k
ell
green
grade
womac
c
omposite
core
difference
efficacy
response
found
regardless
degree
measured
oa
patients
grade
suggesting
strength
duration
pain
relief
observed
following
rtx
treatment
phase
study
may
also
expected
larger
population
patients
advanced
oa
confirm
potential
rtx
benefit
patients
waiting
total
knee
replacements
analysis
performed
applying
composite
score
womac
plus
womac
c
traditionally
used
assess
patients
qualification
knee
replacement
see
table
patients
could
qualify
total
knee
replacement
womac
c
showed
clear
improvement
following
treatment
improved
least
versus
control
group
effect
see
figure
sustained
least
days
signal
seem
degrade
day
many
patients
followed
day
day
indicate
potential
drug
effect
persist
responders
months
numbers
although
encouraging
need
confirmed
trials
larger
number
patients
sorrento
proposed
phase
trials
table
responder
analysis
day
week
subjects
baseline
combined
womac
pain
subscale
womac
c
function
subscale
parameter
response
ug
rtx
saline
control
womac
pain
function
improvement
responder
defined
combined
score
womac
pain
subscale
womac
c
function
subscale
least
decrease
baseline
day
week
note
subjects
without
day
data
included
sorrento
confirmed
pursuing
rtx
treatment
oa
pain
following
traditional
development
program
based
positive
results
phase
trial
also
add
studies
focusing
demonstrating
value
rtx
alternative
tkr
surgery
resiniferatoxin
rtx
thousand
times
hotter
pure
capsaicin
billion
scoville
units
versus
high
affinity
afferent
sensory
pain
nerves
resiniferatoxin
binds
receptors
present
selectively
ablates
nerve
endings
responsible
pain
signals
experienced
delivered
peripherally
joint
space
transient
nerve
ending
ablation
effect
profound
clinical
benefits
lasting
months
years
shown
canine
multicenter
phase
study
assess
safety
define
maximally
tolerated
dose
resiniferatoxin
administered
knee
joint
patients
moderate
severe
pain
associated
osteoarthritis
knee
study
trial
cohorts
patients
received
increasing
doses
resiniferatoxin
maximum
tolerated
dose
mtd
achieved
primary
objective
study
evaluate
safety
resiniferatoxin
identify
recommended
dose
phase
trials
secondary
objective
assess
preliminary
efficacy
resiniferatoxin
measured
assessing
changes
intensity
pain
using
score
womac
index
widely
used
proprietary
validated
pain
questionnaire
information
trial
found
information
upcoming
phase
trials
total
knee
replacement
surgery
deferment
pain
osteroarthritis
pain
found
trial
references
sorrento
therapeutics
sorrento
clinical
stage
biopharmaceutical
company
developing
new
therapies
treat
cancers
sorrento
multimodal
multipronged
approach
fighting
cancer
made
possible
extensive
platforms
including
key
assets
fully
human
antibodies
library
clinical
stage
therapies
conjugates
adcs
clinical
stage
oncolytic
virus
sorrento
also
developing
potential
antiviral
therapies
vaccines
coronaviruses
including
diagnostic
test
solutions
including
sorrento
commitment
therapies
patients
also
demonstrated
effort
advance
agonist
pain
management
small
molecule
resiniferatoxin
rtx
lidocaine
topical
system
treatment
neuralgia
rtx
completed
phase
ib
trial
intractable
pain
associated
cancer
completing
phase
trial
osteoarthritis
patients
approved
fda
february
information
visit
statements
press
release
statements
made
presentation
meeting
contain
statements
related
sorrento
therapeutics
safe
harbor
provisions
section
private
securities
litigation
reform
act
subject
risks
uncertainties
could
cause
actual
results
differ
materially
projected
statements
include
statements
regarding
expectations
sorrento
subsidiaries
technologies
product
candidates
including
limited
resiniferatoxin
rtx
potency
potential
pain
relief
capabilities
potential
duration
pain
relief
rtx
expected
optima
therapeutic
dose
rtx
future
clinical
trials
safety
efficacy
rtx
expected
timing
last
visit
last
patient
year
clinical
potential
rtx
ability
rtx
alternative
pain
management
option
control
refactory
pain
expected
commencement
phase
phase
trials
rtx
completion
additional
enabling
preclinical
studies
potential
impact
elective
surgeries
total
knee
replacement
oa
knee
pain
potential
future
studies
focusing
demonstrating
value
rtx
alternative
tkr
surgery
risks
uncertainties
could
cause
actual
results
differ
materially
adversely
expressed
statements
include
limited
risks
related
sorrento
subsidiaries
technologies
prospects
including
limited
rtx
risks
related
seeking
regulatory
approvals
conducting
obtaining
results
clinical
trials
including
limited
study
trial
prior
rtx
studies
animals
costs
associated
rtx
clinical
trials
risks
prior
test
study
trial
results
may
replicated
future
studies
trials
clinical
commercial
success
rtx
viability
success
using
rtx
treatments
certain
therapeutic
areas
including
oa
risks
related
global
impact
risks
described
sorrento
recent
periodic
reports
filed
securities
exchange
commission
including
sorrento
annual
report
form
year
ended
december
subsequent
quarterly
reports
form
filed
securities
exchange
commission
including
risk
factors
set
forth
filings
investors
cautioned
place
undue
reliance
statements
speak
date
release
undertake
obligation
update
statement
press
release
except
required
law
media
investor
relations
alexis
nahama
svp
corporate
development
head
rtx
program
telephone
email
mediarelations
sorrento
logo
registered
trademarks
sorrento
therapeutics
trademarks
sorrento
therapeutics
trademark
owned
scilex
pharmaceuticals
trademarks
property
respective
owners
sorrento
therapeutics
rights
reserved
https
pmc
articles
sorrento
therapeutics
ark
animal
health
internal
data
file
photos
accompanying
announcement
available
https
newsroom
attachmentng
https
newsroom
attachmentng
